XML 27 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information
12 Months Ended
Dec. 31, 2013
Segment Information [Abstract]  
Segment Information
18. Segment Information

BioTime’s executive management team represents its chief decision maker.  To date, BioTime’s management has viewed BioTime’s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for human embryonic stem cell research.  As a result, the financial information disclosed materially represents all of the financial information related to BioTime’s sole operating segment.